Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapy for primary and metastatic cancers

A functional, nasopharyngeal carcinoma technology, applied in the direction of fermentation, unknown raw materials, botanical equipment and methods, etc.

Active Publication Date: 2006-05-31
SHANGHAI SUNWAY BIOTECH
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] In conclusion, the prior art has shown that it is possible to treat cancer within a limited capacity using different techniques and treatments, however many of these treatments have some significant disadvantages

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapy for primary and metastatic cancers
  • Therapy for primary and metastatic cancers
  • Therapy for primary and metastatic cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Adenovirus is usually a double-stranded DNA genome virus that causes respiratory, intestinal, and eye infections in humans or animals. The virus that causes the common cold is an adenovirus. The oncolytic virus of the present invention includes genetically engineered adenovirus Ad5 variants. The present invention uses specific genetic engineering variants of the Ad5 virus, including S98-001 (SeqID#1) or S98-002 (SeqID#2). Although not wanting to be bound by theory, it is well known that human infection with wild-type Ad5 can heal itself. In addition, Ad5 adenovirus has been routinely used as a gene therapy vector because there is no report that DNA fragments of the Ad5 genome can be integrated into the genome of human cells. Therefore, the present invention also adopts the synchronization of injection of specific oncolytic virus and high temperature to inhibit cancer at the injection site and far away from the virus injection site. Although oncolytic Ad5 variants are used a...

Embodiment 2

[0099] In order to determine an effective dosage regimen for animals (e.g., including humans) treated with the compositions and methods of the present invention, 5 dosage levels of H101 (SEQID#1) are used. Recombinant adenovirus is administered to patients with advanced solid tumors by intratumor injection. One goal is to determine the maximum drug resistance ("MTD") and the safety of intratumoral injection of H101 (SEQID#1). The 5 levels of H101 (SEQID#1) used are shown in Table 2, and the dose increase curve is shown in Figure 3. Each of the 5 independent dose levels includes 3 patients. The dose of DLT in 2 patients was determined as MTD, where DLT included influenza-like grade 4 toxicity due to H101 (SEQID#1), local reaction grade 4 toxicity at the injection site of H101 (SEQID#1), or due to Any toxicity of other grade 3 severity produced by H101 (SEQID#1). If one of three patients develops DLT, that group will treat a total of 6 patients.

[0100] Level

H101 (vi...

Embodiment 3

[0104] Use oncolytic virus S98-001 (SEQ ID#1) synchronized with high temperature to treat cancer patients. The patient’s date of birth was June 10, 1943. He was diagnosed with nasopharyngeal carcinoma in 1990. After a period of treatment with radiotherapy, the development of the primary tumor is clinically controlled. However, during these years, two tumors in the right neck and supraclavicular area slowly developed. At the end of 2001, these two tumors were treated with radiotherapy (cobalt-60, DT 34 Gy / 17F / 24d) combined with high temperature. Unfortunately, these treatments did not inhibit the progression of the two tumors. The patient was hospitalized at the beginning of February 2002. Before being treated with the oncolytic virus S98-001 (SEQID#1) synchronized with the high temperature, the patient underwent a physical examination. The patient is generally in good physical condition, but his nasopharyngeal tissue is nodularly thickened and slightly congested. The surfaces of t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compositions and methods for removing tumor cells in a patient with at least one tumor site. More specifically, the method comprises contacting in vivo at least one tumor cell within the tumor with a cytolytic agent under cytolytic conditions to form a treated tumor; and applying a sufficient in vivo stimulus to the treated tumor to form a stimulated tumor. tumor. Compositions and methods for shrinking local tumors or distant metastatic tumors, or both, in a patient are included. In a preferred aspect, the method of shrinking a tumor in a patient comprises contacting stimulated tumor cells with a cytolytic agent in vivo. Stimulation directed at the tumor cells can increase the levels of chaperone proteins within the tumor cells. The combination of cytolytic agents and tumor cell stimulation, wherein the stimulation is applied simultaneously or sequentially, results in shrinkage of the directly treated tumor. Furthermore, distant or metastatic tumors not directly treated are also reduced by introducing a cytolytic agent to stimulated tumor cells within the first tumor ("treated tumor" or "localized tumor"). In order to optimize the effect of tumor shrinkage, the preferred method steps comprising introducing a cytolytic agent and stimulating the tumor cells are repeated.

Description

Background of the invention [0001] This application claims priority to a US provisional patent application with serial number 60 / 443,095, titled "Treatment of Metastatic Carcinoma", filed on January 28, 2003, and the entire content of which is incorporated herein by reference. [0002] One aspect of the present invention relates to an immunotherapy for the treatment of metastatic tumors. The immunotherapeutic agents and methods of the present invention involve the simultaneous or sequential administration of physiological stress (such as heat) and genetically engineered oncolytic viruses to the treatment area, resulting in subsequent local and distal tumor regression. [0003] Cancer can be defined as a malignant neoplasm in any part of the human or animal body. Cancer that spreads locally or to the distal part of the body is called metastasis. An example of metastasis is the migration of cells from a malignant tumor via the bloodstream or lymph fluid. There are a variety of cance...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/76A61K35/74A61K35/763A61K35/765A61K35/766A61K38/19A61K38/55A61K41/00A61P35/00C12N7/00C12N7/04C12N15/861
CPCA61K38/191A61K41/0052C12N7/00C12N15/86C12N2710/10321C12N2710/10343C12N2710/10371A61K35/765A61K38/1709A61K38/1761A61K38/57A61K35/74A61K35/76A61K35/763A61K35/766A61P13/08A61P35/00A61P43/00Y02A50/30A61K2300/00
Inventor 胡放吴波
Owner SHANGHAI SUNWAY BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com